BioSpace News Archive

Harrow Health, Inc., an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, announced that it priced an underwritten registered offering of 2,376,426 shares of its common stock at a price of $10.52 per share for aggregate gross proceeds of $25 million.

Harrow announced that it has entered into a binding agreement for the acquisition of the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board.

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India Private Limited).

IRLAB Therapeutics AB announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 vaccine ReCOV in the Philippines.

Poolbeg Pharma announces that it has acquired an exclusive licence from InsuCaps Limited, a sister company of AnaBio Technologies, to use InsuCaps’ patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome related diseases including obesity, pre-diabetes and diabetes.

Nexstim Plc announces that it has received an order for two NBT® systems through Canadian Health Solutions, the Company’s distributor in Canada.

NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to advance NMD670 into a Phase II clinical study in patients of spinal muscular atrophy (SMA) Type 3.